Drug Profile


Alternative Names: ASP 9785; MDV 3100; Xtandi

Latest Information Update: 09 Jul 2017

Price : $50

At a glance

  • Originator University of California at Los Angeles; University of Texas M. D. Anderson Cancer Center
  • Developer Astellas Pharma; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Medivation; National Cancer Institute (USA); Queen Mary University of London; The Prostate Cancer Clinical Trials Consortium; University of California, Davis; University of Chicago
  • Class Antineoplastics; Benzamides; Fluorobenzenes; Imidazolidines; Nitriles; Small molecules; Thiones
  • Mechanism of Action Androgen receptor antagonists; Apoprotein stimulants; Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase II Breast cancer; Endometrial cancer; Hepatocellular carcinoma; Salivary gland cancer
  • Phase I Pancreatic cancer

Most Recent Events

  • 06 Jul 2017 M.D. Anderson Cancer Center, in collaboration with Novartis and Astellas Pharma, plans a phase I trial for Breast Cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT03207529)
  • 02 Jun 2017 Pharmacokinetics and safety data from a clinical trial in healthy volunteers presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2017 Astellas Pharma completes a pharmacokinetics and safety trial in healthy volunteers in China before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top